Cargando…

Sodium-glucose cotransporter 2 inhibitors in obese patients with heart failure

Detalles Bibliográficos
Autores principales:	Kato, Shingo, Horita, Nobuyuki, Utsunomiya, Daisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Via Medica 2023
Materias:	Clinical Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987532/ https://www.ncbi.nlm.nih.gov/pubmed/36790045 http://dx.doi.org/10.5603/CJ.a2023.0004

Ejemplares similares

Sodium-glucose cotransporter 2 inhibitors in Asian patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease
por: Kato, Shingo, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review
por: Roy, Raj, et al.
Publicado: (2023)

Effects of Sodium-Glucose Cotransporter Inhibitor Use in Type 2 Diabetes Mellitus Patients With Heart Failure
por: Choday, Silpa, et al.
Publicado: (2023)

The Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Improving Morbidity and Mortality of Heart Failure: A Systematic Review
por: Thiagaraj, Suvedha, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Therapy for the Primary and Secondary Prevention of Heart Failure in Patients With and Without Type 2 Diabetes Mellitus: A Systematic Review
por: Wahinya, Maureen, et al.
Publicado: (2023)

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)

Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients
por: Kubica, Jacek, et al.
Publicado: (2023)

Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review
por: Georgiou, Petros, et al.
Publicado: (2021)

Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors to Decrease the Risk of Cardiovascular Diseases: A Systematic Review
por: Moparthi, Kiran Prasad, et al.
Publicado: (2023)

Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis
por: Lee, Yeong-Min, et al.
Publicado: (2022)

Sacubitril/valsartan, sodium‐glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy
por: Norre, Tobias, et al.
Publicado: (2022)

Benefits of Taking Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: A Systematic Review
por: Sarker, Aditi, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of the Positive Implications on Cardiovascular and Renal Health and Dynamics for Clinical Practice
por: Erdem, Saliha, et al.
Publicado: (2023)

The Effects of Sodium-Glucose Cotransporter-2 Inhibitors (SLGT-2i) on Cardiovascular and Renal Outcomes in Non-diabetic Patients: A Systematic Review
por: Giri Ravindran, Suganya, et al.
Publicado: (2022)

Overview of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Non-diabetic Heart Failure Patients
por: Balan, Irina, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus
por: Srinivas, Natasha, et al.
Publicado: (2021)

Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure
por: Grubić Rotkvić, Petra, et al.
Publicado: (2020)

Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
por: Dutka, Mieczysław, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and Genital Infections in Patients With Diabetic Mellitus and Concomitant Coronary Artery Disease: A Single-Center Experience
por: Shah, Bhupesh R, et al.
Publicado: (2022)

Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients With Diabetes and Chronic Kidney Disease (CKD): A Meta-analysis of Randomized Control Trials
por: Jamil, Sidra, et al.
Publicado: (2022)

Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy
por: Naito, Ryo, et al.
Publicado: (2021)

Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu
Publicado: (2021)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
por: Cao, Yang, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure?
por: McDowell, Kirsty, et al.
Publicado: (2021)

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
por: Li, Juexing, et al.
Publicado: (2022)

Sodium-Glucose Co-transporter 2 Inhibitors/Gliflozins: A New Miracle Therapy for Heart Failure Patients Irrespective of Diabetes Status?
por: Ehsan, Paghunda, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient
por: Severino, Paolo, et al.
Publicado: (2021)

Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure
por: Chen, KangYu, et al.
Publicado: (2023)

Potential Benefits of Sodium-Glucose Transporter-2 Inhibitors in the Symptomatic and Functional Status of Patients With Heart Failure: A Systematic Review and Meta-Analysis
por: Bhalla, Sushen, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey
por: Cappetta, Donato, et al.
Publicado: (2021)

Heart Failure Treatments Such As Angiotensin Receptor/Neprilysin Inhibitor Improve Heart Failure Status and Glucose Metabolism
por: Kashiwagi, Yusuke, et al.
Publicado: (2022)

In Reply to “Letter Regarding ‘Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Urolithiasis’”
por: Anan, Go, et al.
Publicado: (2023)

Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure
por: Kambara, Takahiro, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter-2 Inhibitor Immediately Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients
por: Ohashi, Naro, et al.
Publicado: (2020)

Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs
por: Zelniker, Thomas A, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure
por: Kurczyński, Dominik, et al.
Publicado: (2022)

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
por: Kolwelter, Julie, et al.
Publicado: (2021)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_70vshn25bc0ipbkpg60cirpvm2